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Outcome of a 12-Year Prospective Study in Postmenopausal
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OBJECTIVE—This study assessed insulin and glucagon secre-
tion in relation to insulin sensitivity in Caucasian women who
develop impaired glucose tolerance (IGT) versus those who
maintain normal glucose tolerance (NGT) over a 12-year period.
RESEARCH DESIGN AND METHODS—At baseline and after
3, 8, and 12 years, glucose tolerance (75-g oral glucose tolerance
test), insulin sensitivity (euglycemic-hyperinsulinemic clamp),
and insulin and glucagon secretion (2- to 5-min responses to 5 g
arginine i.v. at fasting, 14 and 25 mmol/l glucose) were deter-
mined in 53 healthy Caucasian women (aged 58 years at baseline)
who all had NGT at baseline.
RESULTS—During the 12-year period, 26 subjects developed
IGT, whereas the remaining 27 subjects maintained NGT
throughout the 12-year period. Subjects developing IGT had
lower insulin sensitivity than those maintaining NGT in the tests
preceding diagnosis of IGT (P  0.05). When judged in relation to
insulin sensitivity, -cell glucose sensitivity and maximal insulin
secretion were lower in those who later developed IGT than in
those maintaining NGT at all tests (P  0.05). Furthermore,
subjects who developed IGT had defective suppression of gluca-
gon secretion by glucose in the test preceding diagnosis of IGT
when they still had NGT (P  0.05).
CONCLUSIONS—- and -cell dysfunction are evident several
years before diagnosis of IGT, and islet dysfunction is manifested
as impaired glucose sensitivity of the - and -cells and reduced
maximal insulin secretion. Diabetes 58:726–731, 2009
I
nsulin resistance is compensated by increased insu-
lin secretion, and impaired glucose tolerance (IGT)
and type 2 diabetes develop when insulin secretion
is not able to fully compensate for insulin resistance
(1–4). Hence, defective islet adaptation to insulin resis-
tance is a main event underlying development of type 2
diabetes. Longitudinal studies when insulin secretion and
insulin sensitivity have been sequentially determined over
time have shown that -cell dysfunction is an early mani-
festation during development of type 2 diabetes. Thus,
insulin secretion, in relation to insulin sensitivity, has been
shown to drop in association with the development of IGT
in Pima Indians (5), in Mexican Americans (6), in Cauca-
sians (7), and in subjects of white, black, and Hispanic
ethnicity in the U.S. (8). This is also supported by the U.K.
Prospective Diabetes Study, which demonstrated that islet
-cell dysfunction, as judged by indirect approaches, is
reduced already at the time of diagnosis of type 2 diabetes
(9,10).
Insulin secretion is regulated by several factors, such as
nutrients, metabolites, gut hormones, and autonomic
nerves (11). Furthermore, insulin secretion can be subdi-
vided in a sensing and triggering action by glucose and
amplifying or inhibitory modulatory effects by other fac-
tors that affect insulin secretion (12). It is currently not
known to what extent the various factors or -cell mech-
anisms contribute to the defective islet function during the
early stages of development of IGT. We have previously
shown that both a defective glucose sensitivity of -cells
as well as reduced maximal insulin secretion exist in
subjects with IGT (13). However, whether these two
defects contribute to the development of IGT and there-
fore are seen also at early stages (i.e., before even IGT
develops) is not known.
In addition to defective -cell function, dysfunction of
glucagon secretion is also of relevance for development of
IGT and type 2 diabetes (14). Thus, it was already demon-
strated in 1970 that a higher glucagon level during meal
ingestion exists in subjects with type 2 diabetes compared
with healthy control subjects (15). Furthermore, it has
been demonstrated that subjects with type 2 diabetes have
elevated levels of glucagon throughout the day (16) and,
moreover, that IGT and type 2 diabetes are associated with
impaired suppression of glucagon secretion (13,17,18). In
addition, we have previously reported that an inappropri-
ately high glucagon secretory response to a standardized
intravenous arginine challenge in normal subjects predicts
development of IGT over a 3-year period (7). Hence,
augmented -cell secretion, together with impaired -cell
function, is an early defect in the development of type 2
diabetes. However, the sequential changes in defective
glucagon secretion during development of IGT has not
been established, and it is not known whether the high
glucagon secretion is explained by impaired glucose sens-
ing of the -cells (i.e., the defective ability of glucose to
suppress glucagon secretion).
The aim of this study was to establish whether impaired
insulin secretion and increased glucagon secretion already
occur before the onset of IGT and, if so, the characteristics
of the dysfunction. To that end, a 12-year longitudinal
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women with normal glucose tolerance (NGT) who, during
this time period, developed IGT or maintained NGT.
Insulin and glucagon secretion were studied using the
glucose-dependent arginine stimulation test (19,20). This
test establishes 1) basal and maximal insulin secretion and
the glucose dependency of insulin secretion and 2) basal
glucagon secretion and glucose-induced suppression of
glucagon secretion. The results were related to insulin
sensitivity as determined with the euglycemic-hyperin-
sulemic clamp (21).
RESEARCH DESIGN AND METHODS
The study was composed of 53 nondiabetic women who belonged to a study
group of a total of 108 women who in 1993 were randomly selected from a
large cohort of 841 postmenopausal women born in 1935 and living in Malmo ¨,
Sweden, to participate in a longitudinal study on islet function and insulin
sensitivity (7,13,22). All subjects were healthy at the time of the baseline
examination in 1993/1994, and none was taking any medication known to
affect carbohydrate metabolism. None of the subjects had a ﬁrst-degree
relative with type 2 diabetes. During the 12-year follow-up, euglycemic-
hyperinsulinemic clamps, glucose-dependent arginine stimulation tests, and
conventional 75-g World Health Organization oral glucose tolerance tests
(OGTTs) were undertaken at baseline and after 3, 8, and 12 years in all
individuals for determination of insulin sensitivity, insulin and glucagon
secretion, and glucose tolerance. Baseline data with characteristics of insulin
and glucagon secretion in this population were published in 2000 (13).
Furthermore, the 3-year follow-up was published in 2000, showing the changes
in insulin and glucagon secretion during the ﬁrst 3 years of the study (7). In the
present study, follow-up after 8 and 12 years was also undertaken but has not
been published before. A total of 71 women had NGT at the baseline
examination (7). The present study reports 12-year follow-up data in 53 of
these subjects. Eighteen subjects were lost to follow-up by the following
reasons: 4 subjects had died, 2 were excluded because of corticosteroid
treatment, 2 were excluded due to malignancies, in 2 subjects it was not
possible to establish the necessary intravenous lines at the follow-up exami-
nations, and 10 subjects had moved out of town or did not want to participate
in the follow-up. These 18 women did not differ from the 53 participants at
baseline regarding body weight, BMI, glucose tolerance, insulin sensitivity, or
insulin or glucagon secretory capacity.
OGTT. An intravenous catheter was inserted into an antecubital vein. After a
baseline sample was taken, an OGTT was performed with a standard World
Health Organization 75-g glucose load. Blood samples were taken after 120
min for analysis of glucose. The subjects spent2hi nasemirecumbent
position.
Glucose-dependent arginine stimulation test. Insulin and glucagon secre-
tion were determined with the intravenous arginine stimulation at three
glucose levels (fasting and 14 and 25 mmol/l) as previously described
(19,20). After an overnight fast, intravenous catheters were inserted into
antecubital veins in both arms. One arm was used for the infusion of glucose
and the other arm for intermittent sampling. The sampling catheter was kept
patent by slow infusion of 0.9% saline when not in use. Baseline samples were
taken at 5 and 2 min. A maximally stimulating dose of arginine hydrochlo-
ride (5 g) was then injected intravenously over 45 s. Samples were taken at 2,
3, 4, and 5 min. A variable-rate 20% glucose infusion was then initiated to raise
and maintain blood glucose at 14 mmol/l. Blood glucose was determined every
5 min bedside, and the glucose infusion adjusted to reach the desired blood
glucose level in 20–25 min. New baseline samples were taken; then arginine (5
g) was again injected and new 2-, 3-, 4-, and 5-min samples were taken. A 2.5-h
resting period was then allowed, after which new baseline samples were
obtained and a high-speed (900 ml/h) 20% glucose infusion for 25–30 min was
used to raise blood glucose to 25 mmol/l, as determined bedside. At this
blood glucose level, new baseline samples were taken and arginine (5 g)
injected, followed by ﬁnal 2-, 3-, 4-, and 5-min samples.
Euglycemic-hyperinsulinemic clamp. Insulin sensitivity was determined
with the euglycemic-hyperinsulinemic clamp (21). After an overnight fast,
intravenous catheters were inserted into antecubital veins in both arms. One
arm was used for infusion of glucose and insulin. The contralateral arm was
used for intermittent sampling, and the catheter was kept patent with slow
infusion of 0.9% saline. A primed constant infusion of insulin (100 units/ml
Actrapid; Novo Nordisk, Bagsvaerd, Denmark) with a constant infusion rate of
0.28 nmol/m
2 body surface per min was started. After 4 min, a variable-rate
20% glucose infusion was added, and its infusion rate was adjusted manually
throughout the clamp procedure to maintain the blood glucose level at 5.0
mmol/l. Blood glucose was determined every 5 min. Samples for analysis of
the achieved insulin concentrations were taken at 60 and 120 min.
Analyses. Blood glucose concentration was determined bedside by the
glucose dehydrogenase technique with a Hemocue (Hemocue, A ¨ngelholm,
Sweden) during the euglycemic-hyperinsulinemic clamp and with an Accu-
trend (Boehringer Mannheim Scandinavia, Bromma, Sweden) during the
glucose-dependent arginine stimulation test. Blood samples for insulin and
glucose from the arginine study and for insulin from the clamp study were
taken in EDTA tubes, were immediately centrifuged, and serum was frozen at
20°C. Serum insulin was analyzed with the double-antibody radioimmuno-
assay technique with the use of guinea pig anti-human insulin antibodies,
mono-
125I-tyr-human insulin, and human insulin standard (Linco Research, St.
Charles, MO). Blood samples for determination of glucagon were taken in
tubes containing aprotinin. They were immediately centrifuged, and plasma
was separated and frozen at 20°C. Plasma glucagon was measured with
double-antibody radioimmunoassay in duplicate using guinea pig anti-human
glucagon antibodies speciﬁc for pancreatic glucagon,
125I-glucagon as tracer,
and glucagon standard (Linco). Plasma glucose concentrations were analyzed
using the glucose oxidase method. All samples were analyzed in duplicate.
Calculations and statistics. Data are presented as means  SE, unless
otherwise stated. For the determination of insulin secretion, the acute insulin
response to arginine was determined as the mean of the 2- to 5-min samples
minus the mean prestimulus insulin concentration at fasting (AIR1), at 14
mmol/l (AIR2), and at 25 mmol/l glucose (AIR3). The slope between AIR1 and
AIR2 was calculated as a measure of the -cell sensitivity to glucose. Similarly,
for the determination of glucagon secretion, the acute glucagon response to
arginine was determined as the mean of the 2- to 5-min samples minus the
mean prestimulus glucagon concentration at fasting (AGR1), at 14 mmol/l
(AGR2), and at 25 mmol/l glucose (AGR3). The slope between AGR1 and
AGR2 was calculated as a measure of the -cell sensitivity to glucose. Insulin
sensitivity was calculated as the glucose infusion rate per kilogram body
weight during the second hour divided by the mean of the insulin levels at 60
and 120 min during the clamp (i.e., nmol glucose  kg body weight
1  min
1 
pmol insulin
1  l
1). To allow comparisons between groups with regard to
-cell secretion in relation to insulin sensitivity, disposition index was
calculated (1–3). This was performed by multiplying the measure of insulin
sensitivity times AIR1, slopeAIR,o rA I R 3, respectively. Statistical comparisons
were undertaken between the two groups of women maintaining NGT or
developing IGT by means of Mann-Whitney U test. Bivariate (Pearson’s)
correlation coefﬁcients were calculated to estimate linear correlation between
variables.
RESULTS
Glucose tolerance. The fasting and 2-h glucose levels
during the OGTT during the four tests are shown in Table
1. At the baseline examination, all 53 subjects had NGT.
Throughout the 12-year follow-up, 26 subjects developed
IGT, whereas 27 subjects remained normal glucose toler-
ant. Eight of the subjects developed IGT after 3 years,
another 14 subjects developed IGT after 8 years, and 4
additional subjects developed IGT after 12 years. Eight
subjects developed type 2 diabetes between the 8- and
12-year follow-up; these subjects had developed IGT after
3 years (two subjects) or after 8 years (six subjects).
Fasting or 2-h glucose did not differ signiﬁcantly between
the two groups at baseline. Both fasting glucose (by 0.6 
0.1 mmol/l; P  0.006) and 2-h glucose (by 0.8  0.2
mmol/l; P  0.012) increased throughout the 12-year study
period in subjects who maintained NGT. Also, in subjects
who developed IGT, fasting and 2-h glucose levels in-
creased and were signiﬁcantly higher than in the group
who maintained NGT after 12 years (P  0.05).
BMI. Both in subjects who developed IGT and in subjects
who maintained NGT, a slight increase in BMI was ob-
served over the 12-year study period (Table 1). At the
baseline test, subjects who later developed IGT had a
slightly higher BMI than those who maintained NGT (P 
0.022), and this difference persisted. Subjects developing
IGT increased BMI by 1.8  0.2 kg/m
2, whereas subjects
who maintained NGT increased BMI by 0.9  0.1 kg/m
2
(P  0.08).
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had a lower insulin sensitivity than those who maintained
NGT already at the baseline examination (P  0.021)
(Table 2). Insulin sensitivity declined during the 12-year
follow-up in subjects who maintained NGT, from 89  18
to 73  17 nmol  kg
1  min
1  pmol
1  l
1 (P  0.001).
Subjects who had developed IGT had lower insulin sensi-
tivity than those who maintained NGT at all tests (Table 2).
Changes in BMI did not correlate to reduction in insulin
sensitivity in subjects who maintained NGT, whereas a
weak correlation was evident in those who developed IGT
(r  0.38; P  0.039).
Insulin secretion. AIR1, AIR2, AIR3, and slopeAIR did not
differ between the two groups at the baseline examination
(Table 2). In the subjects who maintained NGT, AIR1,
slopeAIR, and AIR3 progressively increased throughout the
12 years (Table 3). Insulin secretion, however, needs to be
estimated in relation to insulin sensitivity (3). By calculat-
ing the disposition index (i.e., multiplying slopeAIR and
AIR3 times insulin sensitivity), it was found that in the
subjects who maintained NGT throughout the 12-year
study period, the disposition index for the two variables
remained stable. In contrast, in the subjects who devel-
oped IGT, these indexes were signiﬁcantly lower than in
subjects who maintained NGT in the tests preceding the
IGT (P  0.05) (Fig. 1). When manifest IGT had developed,
disposition index further deteriorated (Fig. 1). In contrast,
disposition index for variable AIR1 did not differ between
the groups throughout the study period (data not shown).
Glucagon secretion. At baseline, slopeAGR was signiﬁ-
cantly lower and AGR2 was signiﬁcantly higher in subjects
who later developed IGT when compared with those who
maintained NGT (P  0.05) (Table 2). In contrast, AGR1
and AGR3 did not differ between the two groups at the
baseline examination. Throughout the 12-year study pe-
riod, slopeAGR and AGR2 were stable in subjects who
maintained NGT, whereas they were lower (slopeAGR)o r
higher (AGR2) in those who later developed IGT (P  0.05)
(Fig. 1).
TABLE 1
Anthropomorphic variables and fasting and 2-h glucose levels during an OGTT in Caucasian postmenopausal women who had NGT
at baseline and after 3 years but developed IGT (n  26 at baseline and after 3 and 8 years and n  18 after 12 years) or maintained
NGT (n  27) at examinations after 8 and 12 years
Baseline 3 years 8 years 12 years
Age (years)
Glucose tolerance
NGT 58 61 66 70
IGT 58 61 66 70
BMI (kg/m
2)
Glucose tolerance
NGT 24.8  0.5 24.8  0.6 25.8  0.6 25.7  0.6
IGT 26.0  0.8* 26.3  1.1* 27.3  1.1* 27.8  1.4*
Fasting glucose (mmol/l)
Glucose tolerance
NGT 4.5  0.1 4.8  0.1 5.2  0.1 5.1  0.1
IGT 4.7  0.1 5.1  0.3 5.4  0.2 5.5  0.2*
2-h glucose (mmol/l)
Glucose tolerance
NGT 6.2  0.1 6.6  0.2 6.7  0.2 6.8  0.2
IGT 6.4  0.2 6.8  0.6 7.9  0.6† 8.9  0.7‡
Data are means  SE. *P  0.05; †P  0.01; ‡P  0.001 as probability level of random difference between the groups.
TABLE 2
Results of the glucose-dependent arginine stimulation test in
Caucasian postmenopausal women who had NGT at baseline but
developed IGT (n  26) or maintained NGT (n  27) during the
12-year follow-up
Maintaining
NGT
Developing
IGT
n 27 26
Fasting insulin (pmol/l) 48  2.5 60  8*
Fasting glucose (mmol/l) 4.6  0.1 4.7  0.1
Insulin at second arginine injection
(pmol/l) 221  18 212  9
Glucose at second arginine injection
(mmol/l) 14.2  0.1 14.2  0.1
Insulin at third arginine injection
(pmol/l) 448  39 508  36
Glucose at third arginine injection
(mmol/l) 28.3  0.2 28.8  0.3
AIR1 (pmol/l) 335  33 394  106
AIR2 (pmol/l) 1,001  119 1,018  126
AIR3 (pmol/l) 994  149 1,081  162
SlopeAIR (pmol/mmol) 62  8.1 64  8.0
Fasting glucagon (ng/l) 66  4.6 64  4.2
Glucagon at second arginine
injection (ng/l) 54  4.6 53  4.6
Glucagon at third arginine injection
(ng/l) 42  2.9 41  2.0
AGR1 (ng/l) 84  7.8 86  11.8
AGR2 (ng/l) 36  4.0 49  6.2*
AGR3 (ng/l) 24  3.6 27  4.1
SlopeAGR (ng/mmol) 5.3  0.5 4.2  0.5*
Glucose infusion rate during min
60–120 of the clamp
(mol/kg/min) 60  35 2  3*
Insulin sensitivity (nmol  kg
1 
min
1  pmol) 89  38 0  4*
Data are means  SE. *P  0.05 as probability level of random
difference between the groups.
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It has earlier been shown that subjects with IGT exhibit
low insulin secretion and high glucagon secretion when
compared with subjects with NGT (13,17). This was also
conﬁrmed in this study. It has not previously been known,
however, whether these islet dysfunctions in IGT also
exist before development of IGT. The novelty of the
present study, therefore, is that insulin secretion is abnor-
mally low and glucagon secretion is abnormally high also
in subjects with NGT who later develop IGT when com-
pared with subjects who maintain NGT over a long period
of time. In fact, the study shows that the combined islet
dysfunction is manifest several years before the onset of
IGT. Furthermore, the study also shows that the main
mechanisms of the -cell dysfunction is reduced glucose
sensitivity of the -cells (slopeAIR) and reduced maximal
insulin secretory capacity (AIR3) and that the main mech-
anism of glucagon hypersecretion is a defective suppres-
sion by glucose of stimulated glucagon secretion rather
than to baseline islet hormone secretion.
The conclusions of this study are based on a 12-year
longitudinal analysis of insulin sensitivity and insulin and
glucagon secretion in Caucasian postmenopausal women
using the glucose-dependent arginine stimulation test for
the determination of insulin and glucagon secretion (19–
21). This is an elaborate test that has the advantage that it
allows a detailed conclusion on glucose sensitivity as well
as basal and maximal islet hormone secretion (19,20). This
is of advantage when compared with the indirect tech-
niques using algorithms from fasting levels of insulin and
glucose (23,24).
At all the test periods, we also undertook determination
of insulin sensitivity using the euglycemic-hyperinsuline-
mic clamp, because it is known that there is a close
relation between islet function and insulin sensitivity and
that insulin secretion needs to be interpreted in relation to
insulin sensitivity (3). The importance of this was evident
in this study in which the absolute insulin secretion was
not signiﬁcantly reduced in the subjects developing IGT.
However, when taking into account the higher demand for
insulin as caused by the insulin resistance, it is clear that
subjects who developed IGT had a poor compensatory
increase secretion as a sign of defective islet function as
evident by the reduced disposition index. Hence, this
study shows that the main defect in -cell function in
subjects developing IGT is the inability to sufﬁciently
compensate the reduced insulin sensitivity with increased
insulin secretion.
The glucose-dependent arginine stimulation test also
allows conclusions on mechanisms of the -cell dysfunc-
tion since it estimates both the glucose sensitivity of the
-cells and the maximal insulin secretion. We found that it
was slopeAIR and AIR3 that were reduced in subjects who
developed IGT. In contrast, basal insulin secretion (AIR1)
was not reduced. This suggests that it is the glucose
sensitivity of the -cell and the maximal insulin response
that are the main -cell dysfunction mechanisms during
development of IGT. The molecular mechanism of -cell
glucose sensing is a complex phenomenon that involves
glucose uptake in the cell, glucose metabolism and pro-
duction of energy and ATP, the opening of ATP-dependent
K
	 channels, and uptake of calcium (12). Furthermore, the
maximal insulin secretion also involves the molecular
mechanisms of storage of insulin in insulin granules and
exocytosis (25). The present results therefore suggest that
subjects with IGT have defects in these mechanisms
already at a stage when NGT is preserved.
The present study also shows that the increase in
glucagon secretion in subjects who develop IGT is evident
already before IGT is manifest (i.e., this also is an early
phenomenon). Hence, high glucagon secretion is indeed
an important risk factor for IGT and type 2 diabetes, and
impaired ability of glucose to suppress glucagon secretion
seems to be a major mechanism (both slopeAGR and AGR2
are abnormal in subjects who develop IGT). The high
glucagon secretion in IGT has been demonstrated before
when compared with subjects with NGT (17,26,27), and a
high glucagon secretion also has been documented (18) in
type 2 diabetes. We have also previously reported that high
glucagon predicts worsening of glucose tolerance over a
3-year study period (7). The novelty of this study is that
high glucagon secretion is evident in subjects who later
develop IGT when compared with subjects who maintain
NGT over a long period of time. The results also suggest
that the mechanism of the high glucagon secretion in the
subjects who later develop IGT is impaired efﬁcacy of
TABLE 3
Insulin sensitivity as determined by the euglycemic-hyperinsu-
linemic clamp, and measures of insulin and glucagon secretion as
obtained from the glucose-dependent arginine stimulation test
(AIR1, slopeAIR, AIR3, and slopeAGR) in Caucasian postmeno-
pausal women who had NGT at baseline and either maintained
NGT throughout the 12-year study period or developed IGT after
3, 8, or 12 years
3-year test 8-year test 12-year test
n
Group
NGT 27 27 27
Later IGT 18 4 0
Manifest IGT 8 22 18
Insulin sensitivity (nmol 
kg
1  min
1 
pmol)
Group
NGT 86  21 76  18 73  17
Later IGT 75  20* 62  17† —
Manifest IGT 66  22 69  16 64  16
AIR1 (pmol/l)
Group
NGT 309  32 382  40 383  42
Later IGT 349  38 360  38 —
Manifest IGT 388  31 346  35 362  68
SlopeAIR (pmol/mmol)
Group
NGT 62  5.8 70  7.8 78  6.2
Later IGT 59  4.9 62  6.1 —
Manifest IGT 56  5.1 58  5.6 52  5.9
AIR3 (pmol/l)
Group
NGT 1,010  138 1,095  150 1,195  130
Later IGT 903  156 991  139 —
Manifest IGT 896  86 922  101 886  110
SlopeAGR (ng/mmol)
Group
NGT 5.9  0.6 5.2  0.5 5.0  0.5
Later IGT 5.1  0.5* 4.3  0.4* —
Manifest IGT 3.1  0.4 3.2  0.4 3.1  0.3
Data are means  SE. *P  0.05 and †P  0.01 as probability level of
random difference between the group with NGT and the group who
later developed IGT. Number of individuals in each group shown in
row 2.
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on suppression of ionic channels in the -cells, as recently
reviewed (28). Another possibility, however, might be
impaired suppression by paracrine factors released from
the -cells, such as insulin itself, 
-aminobutyric acid, or
zinc, all of which are thought to inhibit glucagon secretion
(28). Further studies are required to establish the mecha-
nism underlying the early impairment of suppression of
glucagon secretion.
The euglycemic-hyperinsulinemic clamp technique is
considered the gold or reference standard for estimating
insulin sensitivity in humans since it estimates the whole-
body glucose disappearance in response to insulin (29). A
limitation of the technique is, however, that it does not
measure the action of insulin to suppress hepatic glucose
production, the determination of which requires the iso-
tope dilution technique (29). Since we did not use the
isotope dilution technique in this study, it is possible that
insulin sensitivity in terms of the total body effect of
insulin to stimulate glucose disappearance is underesti-
mated in subjects with insulin resistance. The degree of
insulin resistance in the subjects who developed IGT
would therefore be less than estimated in this study, and,
consequently, the islet dysfunction when calculated as
disposition index would also be less than estimated.
In conclusion, this study shows that insulin secretion
(when judged in relation to insulin sensitivity) is already
low before IGT is diagnosed and that this -cell dysfunc-
tion is explained by reduced glucose sensitivity of the
-cells and the maximal -cell secretory capacity. Further-
more, the study also shows that glucagon secretion is
increased in subjects who develop IGT and that this is
explained by impaired ability of glucose to suppression of
glucagon secretion. Thus, the results show that islet dys-
function is critical for development of IGT and type 2
diabetes and that these pathophysiological events already
start when subjects are normal glucose tolerant.
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FIG. 1. Insulin secretion (disposition indexes [DIs]) for slopeAIR and AIR3 and glucagon secretion (slopeAGR) as obtained from the
glucose-dependent arginine-stimulation test and the euglycemic-hyperinsulinemic clamp at baseline and after 3, 8, and 12 years in healthy women
with NGT at baseline (n  53). The subjects were divided in groups who maintained NGT throughout the 12-year period (n  27) or developed
IGT after 3 years (n  6), after 8 years (n  12), or after 12 years (n  4). Means  SE are shown. Asterisks indicate the probability level of
random difference between the group who maintained NGT versus the subjects with NGT who later developed IGT. *P < 0.05; **P < 0.01. f,
indicates subjects who already have developed IGT.
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